{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:21:16Z","timestamp":1790612476752,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100019945","name":"Clinical and Translational Science Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","award":["UL1 TR000457"],"award-info":[{"award-number":["UL1 TR000457"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]},{"name":"APS ACTION Global Lead Coordinator"},{"name":"Elena Gkrouzman"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study focused on the prevalence and impact of ANA in aPL-positive patients without concomitant systemic autoimmune rheumatic diseases (SARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from aPL-positive patients with or without Revised Sapporo APS classification criteria were retrieved from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Patients with concomitant SARDs were excluded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 430 aPL-positive patients were included in the analysis, 56% ANA-positive (ANA+) and 44% ANA-negative (ANA\u2212). ANA positivity was significantly associated with history of haematologic manifestations (persistent autoimmune haemolytic anaemia, thrombocytopenia, leukopenia and\/or lymphopenia) (16% of ANA+ vs 7% of ANA\u2212, P\u2009=\u20090.006). Triple aPL-positivity was more frequent in the ANA+ subgroup (P\u2009=\u20090.02), along with low baseline C3 and C4 levels (P\u2009=\u20090.05 and P\u2009=\u20090.009, respectively), and higher frequency for ENA. Among aPL-positive patients with no APS classification, ANA+ patients showed a higher rate of arthritis (P\u2009=\u20090.006). Among female patients who have experienced at least one pregnancy, 113 were ANA+ and 96 were ANA\u2212; ANA\u2212 patients had a higher number of pregnancies (P\u2009=\u20090.018), and number of live births (P\u2009=\u20090.014). A wider proportion of ANA+ patients were treated with HCQ (P\u2009&amp;lt;\u20090.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>When we analysed aPL-positive patients with no other SARDs, ANA status was not associated with thrombosis or pregnancy morbidity. Interestingly, ANA+ patients showed higher rates of systemic autoimmune features, including haematologic manifestations, multiple aPL positivity, lower complement levels, ENA positivity, and joint involvement, and were more often treated with HCQ. Finally, aPL-positive subjects who were ANA\u2212 had a higher rate of pregnancies and live births.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae583","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T16:45:32Z","timestamp":1729269932000},"page":"2862-2867","source":"Crossref","is-referenced-by-count":11,"title":["ANA-positive <i>versus<\/i> ANA-negative Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d)"],"prefix":"10.1093","volume":"64","author":[{"given":"Irene","family":"Cecchi","sequence":"first","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin,","place":["Italy"]},{"name":"Department of Clinical and Biological Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1941-2606","authenticated-orcid":false,"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin,","place":["Italy"]},{"name":"Department of Clinical and Biological Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Grazietta","family":"Foddai","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin,","place":["Italy"]},{"name":"Department of Clinical and Biological Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Barinotti","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin,","place":["Italy"]},{"name":"Department of Clinical and Biological Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-1808","authenticated-orcid":false,"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo , S\u00e3o Paulo,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2064-6071","authenticated-orcid":false,"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[{"name":"Senior Scientist, University of Padova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1043","authenticated-orcid":false,"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"additional","affiliation":[{"name":"Autoinmune Diseases Research Unit, Biobizkaia Health Research Institute, UPV\/EHU , Barakaldo,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-2976","authenticated-orcid":false,"given":"H Michael","family":"Belmont","sequence":"additional","affiliation":[{"name":"New York University Langone Medical Center , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chary","family":"Lopez Pedrera","sequence":"additional","affiliation":[{"name":"Rheumatology Service\/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)\/ Reina Sofia University Hospital\/ University of Cordoba , C\u00f3rdoba,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Fortin","sequence":"additional","affiliation":[{"name":"Centre ARThrite\u2014CHU de Qu\u00e9bec \u2013 Universit\u00e9 Laval , Quebec, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5847","authenticated-orcid":false,"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[{"name":"University of Milan , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"de Jes\u00fas","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro , Rio de Janeiro,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Hokkaido University Hospital , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-8882","authenticated-orcid":false,"given":"Lanlan","family":"Ji","sequence":"additional","affiliation":[{"name":"Peking University First Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Efthymiou","sequence":"additional","affiliation":[{"name":"University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Ware","family":"Branch","sequence":"additional","affiliation":[{"name":"University of Utah and Intermountain Healthcare , Salt Lake City, UT,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Nalli","sequence":"additional","affiliation":[{"name":"University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-5644","authenticated-orcid":false,"given":"Esther","family":"Rodriguez-Almaraz","sequence":"additional","affiliation":[{"name":"Hospital Universitario, 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-492X","authenticated-orcid":false,"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, IDIBAPS, University of Barcelona , Barcelona, Catalonia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S","family":"Knight","sequence":"additional","affiliation":[{"name":"University of Michigan , Ann Arbor, MI,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Artim-Esen","sequence":"additional","affiliation":[{"name":"Istanbul University School of Medicine , Istanbul,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch , Galveston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[{"name":"School of Cardiovascular & Metabolic Medicine & Sciences, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2032-390X","authenticated-orcid":false,"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[{"name":"University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[{"name":"Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital , Turin,","place":["Italy"]},{"name":"Department of Clinical and Biological Sciences, University of Turin , Turin,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"2025070312515559200_keae583-B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025070312515559200_keae583-B2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2018.00969","article-title":"Cellular and molecular mechanisms of anti-phospholipid syndrome","volume":"9","author":"Radic","year":"2018","journal-title":"Front Immunol"},{"key":"2025070312515559200_keae583-B3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025070312515559200_keae583-B4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/08916930902827918","article-title":"The interplay between the antiphospholipid syndrome and systemic lupus erythematosus","volume":"42","author":"Tincani","year":"2009","journal-title":"Autoimmunity"},{"key":"2025070312515559200_keae583-B5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2025070312515559200_keae583-B6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2018.01.027","article-title":"Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: are they different entities?","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025070312515559200_keae583-B7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/BOR.0b013e32832effdd","article-title":"Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?","volume":"21","author":"Shoenfeld","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"2025070312515559200_keae583-B8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025070312515559200_keae583-B9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0961203307077993","article-title":"Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus","volume":"16","author":"Tarr","year":"2007","journal-title":"Lupus"},{"key":"2025070312515559200_keae583-B10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23584","article-title":"The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository","volume":"71","author":"Unlu","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025070312515559200_keae583-B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2007.11.004","article-title":"Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?","volume":"30","author":"Andreoli","year":"2008","journal-title":"J Autoimmun"},{"key":"2025070312515559200_keae583-B12","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/0961203320950477","article-title":"Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality","volume":"29","author":"Riancho-Zarrabeitia","year":"2020","journal-title":"Lupus"},{"key":"2025070312515559200_keae583-B13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/0961203320940776","article-title":"Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry","volume":"29","author":"Zuily","year":"2020","journal-title":"Lupus"},{"key":"2025070312515559200_keae583-B14","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/rheumatology\/kez596","article-title":"Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients","volume":"60","author":"Sciascia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025070312515559200_keae583-B15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0961203312437810","article-title":"APS ACTION\u2014antiphospholipid syndrome alliance for clinical trials and international networking","volume":"21","author":"Erkan","year":"2012","journal-title":"Lupus"},{"key":"2025070312515559200_keae583-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025070312515559200_keae583-B17","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025070312515559200_keae583-B18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2025070312515559200_keae583-B19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025070312515559200_keae583-B20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025070312515559200_keae583-B21","doi-asserted-by":"crossref","first-page":"105297","DOI":"10.1016\/j.jbspin.2021.105297","article-title":"Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: a multicenter retrospective study","volume":"89","author":"Ricard","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2025070312515559200_keae583-B22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002881","article-title":"Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: french multicentric cohort study","volume":"9","author":"Guedon","year":"2023","journal-title":"RMD Open"},{"key":"2025070312515559200_keae583-B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","journal-title":"J Thromb Haemost"},{"key":"2025070312515559200_keae583-B24","doi-asserted-by":"crossref","first-page":"18005","DOI":"10.1038\/nrdp.2018.5","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025070312515559200_keae583-B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semarthrit.2017.12.006","article-title":"Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management","volume":"48","author":"Radin","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025070312515559200_keae583-B26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/096120339700600314","article-title":"Primary antiphospholipid syndrome evolving into systemic lupus erythematosus","volume":"6","author":"Seisdedos","year":"1997","journal-title":"Lupus"},{"key":"2025070312515559200_keae583-B27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.md.0000172074.53583.ea","article-title":"Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?","volume":"84","author":"G\u00f3mez-Puerta","year":"2005","journal-title":"Medicine"},{"key":"2025070312515559200_keae583-B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10067-013-2472-3","article-title":"Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?","volume":"33","author":"Freire","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2025070312515559200_keae583-B29","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025070312515559200_keae583-B30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025070312515559200_keae583-B31","doi-asserted-by":"crossref","first-page":"1759720X211073001","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025070312515559200_keae583-B32","doi-asserted-by":"crossref","first-page":"103794","DOI":"10.1016\/j.jri.2022.103794","article-title":"Antinuclear antibodies positivity in women in reproductive age: from infertility to adverse obstetrical outcomes\u2014A meta-analysis","volume":"155","author":"Ticconi","year":"2023","journal-title":"J Reprod Immunol"},{"key":"2025070312515559200_keae583-B33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025070312515559200_keae583-B34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"2025070312515559200_keae583-B35","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0049-3848(19)30366-4","article-title":"Managing antiphospholipid syndrome in pregnancy","volume":"181","author":"Schreiber","year":"2019","journal-title":"Thromb Res"},{"key":"2025070312515559200_keae583-B36","doi-asserted-by":"crossref","first-page":"1186439","DOI":"10.3389\/fimmu.2023.1186439","article-title":"Anti-dense fine speckled 70 (DFS70) autoantibodies: correlates and increasing prevalence in the United States","volume":"14","author":"Dinse","year":"2023","journal-title":"Front Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae583\/60835616\/keae583.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2862\/60835616\/keae583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2862\/60835616\/keae583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T16:52:07Z","timestamp":1751561527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2862\/7826633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,18]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae583","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,18]]}}}